Jung W. Eun

Suwon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

A Comprehensive Understanding of DCTPP1 as an Emerging Therapeutic Target in Liver Cancer.

A Comprehensive Understanding of DCTPP1 as an Emerging Therapeutic Target in Liver Cancer.

Journal: Current issues in molecular biology

Published: June 30, 2026

Comprehensive Multi-Omics Characterization of CYP2R1 as a Diagnostic and Functional Biomarker in Hepatocellular Carcinoma.

Comprehensive Multi-Omics Characterization of CYP2R1 as a Diagnostic and Functional Biomarker in Hepatocellular Carcinoma.

Journal: Medical sciences (Basel, Switzerland)

Published: February 19, 2026

Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation.

Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation.

Journal: Molecular oncology

Published: February 10, 2026

Systematic transcriptomic analysis of UDP-glucuronosyltransferases reveals UGT2B11 as a diagnostic and metabolic marker in hepatocellular carcinoma.

Systematic transcriptomic analysis of UDP-glucuronosyltransferases reveals UGT2B11 as a diagnostic and metabolic marker in hepatocellular carcinoma.

Journal: BMC cancer

Published: February 05, 2026

Plasma interleukin-8 as a predictive biomarker for tyrosine kinase inhibitor response in advanced hepatocellular carcinoma.

Plasma interleukin-8 as a predictive biomarker for tyrosine kinase inhibitor response in advanced hepatocellular carcinoma.

Journal: Discover oncology

Published: January 09, 2026

Correspondence to editorial on "Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector".

Correspondence to editorial on "Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector".

Journal: Clinical and molecular hepatology

Published: December 13, 2025

DKK1 Suppresses Hippo Signaling via PIP3-OGT-LRP6 O-GlcNAcylation in Hepatocellular Carcinoma.

DKK1 Suppresses Hippo Signaling via PIP3-OGT-LRP6 O-GlcNAcylation in Hepatocellular Carcinoma.

Journal: Cancer communications (London, England)

Published: November 12, 2025

RP11-Derived Long Non-Coding RNAs in Hepatocellular Carcinoma: Hidden Treasures in Plain Sight.

RP11-Derived Long Non-Coding RNAs in Hepatocellular Carcinoma: Hidden Treasures in Plain Sight.

Journal: Oncology research

Published: August 22, 2025

Serum Extracellular Vesicle-Associated GULP1 Is a Key Indicator of Hepatocellular Carcinoma.

Serum Extracellular Vesicle-Associated GULP1 Is a Key Indicator of Hepatocellular Carcinoma.

Journal: Oncology research

Published: July 15, 2025

CTC-537E7.3 as a Liver-Specific Biomarker for Hepatocellular Carcinoma: Diagnostic and Prognostic Implications.

CTC-537E7.3 as a Liver-Specific Biomarker for Hepatocellular Carcinoma: Diagnostic and Prognostic Implications.

Journal: Current issues in molecular biology

Published: June 13, 2025

Reply to correspondence 2 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".

Reply to correspondence 2 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".

Journal: Clinical and molecular hepatology

Published: May 26, 2025

A Novel Liver-Specific Pseudogene Biomarker, BMS1P8, for Diagnosis and Prognosis in Hepatocellular Carcinoma.

A Novel Liver-Specific Pseudogene Biomarker, BMS1P8, for Diagnosis and Prognosis in Hepatocellular Carcinoma.

Journal: Frontiers in bioscience (Landmark edition)

Published: May 19, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026